Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
Completed
- Conditions
- Metastatic Breast Cancer
- Registration Number
- NCT00876070
- Lead Sponsor
- SCRI Development Innovations, LLC
- Brief Summary
This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 198
Inclusion Criteria
- Patients that have received Abraxane chemotherapy greater than three months from the time of chart review.
- Patients that have received taxane chemotherapy greater than three months from the time of chart review.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Describe patient demographics, disease and treatment characteristics. 6 months
- Secondary Outcome Measures
Name Time Method Describe detailed treatment and response characteristics. 6 months Describe resource utilization and cost variables. 6 months
Trial Locations
- Locations (2)
Tennessee Oncology, PLLC
🇺🇸Nashville, Tennessee, United States
Georgia Cancer Specialists
🇺🇸Atlanta, Georgia, United States